Vitamin D3-induced IDO+ Tolerogenic DCs Reduces the Severity of Experimental Autoimmune Encephalomyelitis

被引：0
|
作者：
Farias, Alessandro S. [1 ,2 ]
Spagnol, Gabriela S. [1 ,2 ]
Pradella, Fernando [1 ,2 ]
Santos, Mariana P. A. [1 ,2 ]
Moraes, Adriel S. [1 ,2 ]
Oliveira, Elaine C. [1 ]
Longhini, Ana Leda F. [1 ]
de Paula, Rosemeire F. O. [1 ]
Santos, Leonilda M. B. [1 ]
机构：
[1] Univ Campinas UNICAMP, Neuroimmunol Unit, Campinas, SP, Brazil
[2] Univ Campinas UNICAMP, Dept Genet Evolut & Bioagents, Neuroimmunomodulat Grp, Campinas, SP, Brazil
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1872 / 1873
页数：2
相关论文
共 50 条
  • [41] Sex-based differences in vitamin D metabolism and susceptibility to experimental autoimmune encephalomyelitis
    Spach, KM
    Hayes, CE
    FASEB JOURNAL, 2005, 19 (05): : A1465 - A1465
  • [42] Association of myelin oligodendrocyte glycoprotein with vitamin D inhibited Experimental autoimmune encephalomyelitis development
    Chiuso-Minicucci, Fernanda
    Ishikawa, Larissa
    Mimura, Luiza
    Silva, Thais
    Zorzella-Pezavento, Sofia
    Fraca, Thais
    Marques, Camila
    Ikoma, Maura
    Okoshi, Marina
    Sartori, Alexandrina
    FASEB JOURNAL, 2014, 28 (01):
  • [43] The vitamin D receptor is necessary for 1α,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice
    Meehan, TF
    DeLuca, HF
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2002, 408 (02) : 200 - 204
  • [44] Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG35-55-induced experimental autoimmune encephalomyelitis
    Wetzel, Lisa A.
    Hurtado, Myrna
    Kaswan, Zoe A. MacDowell
    Mccusker, Robert H.
    Steelman, Andrew J.
    BRAIN, BEHAVIOR, & IMMUNITY - HEALTH, 2020, 7
  • [45] AML-associated translocation products block vitamin D3-induced differentiation by sequestering the vitamin D3 receptor
    Puccetti, E
    Obradovic, D
    Beissert, T
    Bianchini, A
    Washburn, B
    Chiaradonna, F
    Boehrer, S
    Hoelzer, D
    Ottmann, OG
    Pelicci, PG
    Nervi, C
    Ruthardt, M
    CANCER RESEARCH, 2002, 62 (23) : 7050 - 7058
  • [46] Disease-modifying capability of murine Flt3-ligand DCs in experimental autoimmune encephalomyelitis
    Papenfuss, Tracey L.
    Kithcart, Aaron P.
    Powell, Nicole D.
    McClain, Melanie A.
    Gienapp, Ingrid E.
    Shawler, Todd M.
    Whitacre, Caroline C.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2007, 82 (06) : 1510 - 1518
  • [47] The TLR7 agonist, imiquimod, increases IFN-β production and reduces the severity of experimental autoimmune encephalomyelitis
    O'Brien, Kate
    Fitzgerald, Denise
    Rostami, Abdolmohamad
    Gran, Bruno
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 221 (1-2) : 107 - 111
  • [48] Oral fingolimod (FTY720) reduces the severity of experimental autoimmune encephalomyelitis and protects against disease progression
    Schubart, Anna
    Seabrook, Tim
    Rausch, Martin
    Mir, Anis K.
    MULTIPLE SCLEROSIS, 2008, 14 : S54 - S55
  • [49] Metformin treatment reduces inflammation, dysmyelination and disease severity in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis
    Gilbert, Emily A. B.
    Livingston, Jessica
    Flores, Emilio Garcia
    Khan, Monoleena
    Kandavel, Harini
    Morshead, Cindi M.
    BRAIN RESEARCH, 2024, 1822
  • [50] Prophylactic exposure to oral riluzole reduces the clinical severity and immune-related biomarkers of experimental autoimmune encephalomyelitis
    Rotolo, Renee A.
    Demuro, Jennifer
    Drummond, Gregory
    Little, Casey
    Johns, Lennart D.
    Betz, Adrienne J.
    JOURNAL OF NEUROIMMUNOLOGY, 2021, 356
12345